Pajjiż: Awstralja
Lingwa: Ingliż
Sors: Department of Health (Therapeutic Goods Administration)
Peginterferon alfa-2a, Quantity: 180 microgram
Echo Therapeutics Pty Ltd
Injection, solution
Excipient Ingredients: acetic acid; water for injections; sodium acetate; sodium chloride; polysorbate 80; benzyl alcohol
Subcutaneous
4 pre-filled syringes with needles
(S4) Prescription Only Medicine
Chronic Hepatitis C (CHC): The combination of PEGASYS and COPEGUS is indicated for the treatment of chronic heptitis C in patients who have received no prior interferon therapy (treatment naive patients) and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin. The combination of PEGASYS and COPEGUS is also indicated for the treatment of chronic hepatitis C in patients with clinically stable human immunodeficiency virus (HIV) co-infection who have previously not received interferon therapy. PEGASYS monotherapy is indicated for the for the treatment of chronic heptitis C in treatment naive patients (see Dosage and Administration; Chronic Hepatitis C: Treatment naive patients). Patients must be 18 years of age or older and have compensated liver disease. Chronic Hepatitis B (CHB): PEGASYS is indicated for the treatment of chronic heptitis B in adult patients with evidence of viral replication and liver inflammation and compensated liver disease.
Visual Identification: Clear, colourless to light yellow solution, practically free from particles.; Container Type: Syringe; Container Material: Glass Type I Clear; Container Life Time: 4 Years; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2003-05-28
PEGASYS® CMI 1.00 1 PEGASYS ® pronounced peg-ah-sis contains the active ingredient peginterferon alfa-2a Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Pegasys pre-filled syringes. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you using Pegasys against the benefits they expect it will have for you. If you have any concerns about using this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. What Pegasys is used for Pegasys contains the active ingredient peginterferon alfa-2a. Pegasys belongs to a group of medicines called interferons. Pegasys is a long-acting interferon. Interferons are proteins that modify the response of the body's immune system to help fight infections and severe diseases. Pegasys is used to treat chronic hepatitis B or C, which are viral infections of the liver. If these viral infections are not managed, in some people, the liver becomes badly damaged and scarred. This is called cirrhosis. Cirrhosis can cause the liver to stop working. Cirrhosis can also be caused by things other than viral infections such as long-term alcoholism. It is not known if Pegasys can prevent liver failure or liver cancer that is caused by hepatitis infection. Most people who get hepatitis B or C carry the virus in their blood for the rest of their lives, unless successfully treated. Most of these people will have some liver damage, but not all feel sick from the disease. For chronic hepatitis B, Pegasys is usually used alone. For chronic hepatitis C, Pegasys is best used in combination with ribavirin tablets. If you are given Pegasys in combination therapy, you should also read the ribavirin Consumer Medicine Information leaflet before use. Pegasys is used alone for chronic hepatitis C only if you cannot take ribavirin tablets for any reason. Pegasys treat Aqra d-dokument sħiħ
Pegasys (peginterferon alfa-2a) solution for injection PI 1.00 1 AUSTRALIAN PRODUCT INFORMATION Pegasys (peginterferon alfa-2a) 1. NAME OF THE MEDICINE Peginterferon alfa-2a 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pegasys 135micrograms solution for injection in pre-filled syringe. Each syringe of 0.5mL solution contains 135 micrograms of peginterferon alfa-2a. Pegasys 180 micrograms solution for injection in pre-filled syringe. Each syringe of 0.5mL solution contains 180 micrograms of peginterferon alfa-2a. Excipient with known effect Benzyl alcohol (10 mg/ 1 ml) For the full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Solution for injection. The solution is clear and colourless to light yellow. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Chronic Hepatitis C (CHC) The combination of Pegasys and ribavirin is indicated for the treatment of chronic hepatitis C in patients who have received no prior interferon therapy (treatment-naïve patients) and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin. The combination of Pegasys and ribavirin is also indicated for the treatment of chronic hepatitis C patients with clinically stable human immunodeficiency virus (HIV) co-infection who have previously not received interferon therapy. Pegasys monotherapy is indicated for the treatment of chronic hepatitis C in treatment-naïve patients (see section 4.2 Dose and Method of Administration). Patients must be 18 years of age or older and have compensated liver disease. Chronic Hepatitis B (CHB) PEGASYS is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and liver inflammation and compensated liver disease. 4.2 DOSE AND METHOD OF ADMINISTRATION Dose Before beginning Pegasys, standard haematological and biochemical laboratory tests are recommended for all patients (see section 4.4 Special Warnings and Precautions for Use). When used in combi Aqra d-dokument sħiħ